COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies

Bin Q. Yang; Justin M. Vader; David S. Lambert; Richard Petrella; Joel D. Schilling; Amanda K. Verma

doi:10.1016/j.trim.2022.101712

COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies

Bin Q. Yang, Justin M. Vader, David S. Lambert, Richard Petrella, Joel D. Schilling, Amanda K. Verma

Research output: Contribution to journal › Article › peer-review

Abstract

De novo donor-specific antibodies (DSAs) are associated with increased risk of antibody-mediated rejection and worse clinical outcomes after orthotopic heart transplant (OHT). No study has reported the production of DSAs after infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in an OHT population. In this retrospective study, we described coronavirus disease 2019 (COVID-19) incidence and clinical course in a large, contemporary OHT cohort. We showed that the case-fatality rate has significantly decreased since the early days of the pandemic, although remains higher than that of the general population. In addition, we found that 10% of OHT recipients developed de novo DSAs or experienced an increase in pre-existing DSAs after COVID-19, with the majority occurring in unvaccinated patients (15% vs 2%). Further studies are necessary to substantiate our findings in an external cohort.

Original language	English (US)
Article number	101712
Journal	Transplant Immunology
Volume	75
DOIs	https://doi.org/10.1016/j.trim.2022.101712
State	Published - Dec 2022
Externally published	Yes

Keywords

COVID-19
Donor specific antibody
Heart transplant

ASJC Scopus subject areas

Transplantation
Immunology and Allergy
Immunology

Access to Document

10.1016/j.trim.2022.101712

Cite this

@article{ffdadee6825b4a8fa23d7ab4edf61f64,

title = "COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies",

abstract = "De novo donor-specific antibodies (DSAs) are associated with increased risk of antibody-mediated rejection and worse clinical outcomes after orthotopic heart transplant (OHT). No study has reported the production of DSAs after infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in an OHT population. In this retrospective study, we described coronavirus disease 2019 (COVID-19) incidence and clinical course in a large, contemporary OHT cohort. We showed that the case-fatality rate has significantly decreased since the early days of the pandemic, although remains higher than that of the general population. In addition, we found that 10% of OHT recipients developed de novo DSAs or experienced an increase in pre-existing DSAs after COVID-19, with the majority occurring in unvaccinated patients (15% vs 2%). Further studies are necessary to substantiate our findings in an external cohort.",

keywords = "COVID-19, Donor specific antibody, Heart transplant",

author = "Yang, {Bin Q.} and Vader, {Justin M.} and Lambert, {David S.} and Richard Petrella and Schilling, {Joel D.} and Verma, {Amanda K.}",

note = "Funding Information: Dr. Yang is supported by NIH grant T32HL007081-41 . The other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = dec,

doi = "10.1016/j.trim.2022.101712",

language = "English (US)",

volume = "75",

journal = "Transplant Immunology",

issn = "0966-3274",

publisher = "Elsevier",

}

TY - JOUR

T1 - COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies

AU - Yang, Bin Q.

AU - Vader, Justin M.

AU - Lambert, David S.

AU - Petrella, Richard

AU - Schilling, Joel D.

AU - Verma, Amanda K.

N1 - Funding Information: Dr. Yang is supported by NIH grant T32HL007081-41 . The other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2022 Elsevier B.V.

PY - 2022/12

Y1 - 2022/12

N2 - De novo donor-specific antibodies (DSAs) are associated with increased risk of antibody-mediated rejection and worse clinical outcomes after orthotopic heart transplant (OHT). No study has reported the production of DSAs after infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in an OHT population. In this retrospective study, we described coronavirus disease 2019 (COVID-19) incidence and clinical course in a large, contemporary OHT cohort. We showed that the case-fatality rate has significantly decreased since the early days of the pandemic, although remains higher than that of the general population. In addition, we found that 10% of OHT recipients developed de novo DSAs or experienced an increase in pre-existing DSAs after COVID-19, with the majority occurring in unvaccinated patients (15% vs 2%). Further studies are necessary to substantiate our findings in an external cohort.

AB - De novo donor-specific antibodies (DSAs) are associated with increased risk of antibody-mediated rejection and worse clinical outcomes after orthotopic heart transplant (OHT). No study has reported the production of DSAs after infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in an OHT population. In this retrospective study, we described coronavirus disease 2019 (COVID-19) incidence and clinical course in a large, contemporary OHT cohort. We showed that the case-fatality rate has significantly decreased since the early days of the pandemic, although remains higher than that of the general population. In addition, we found that 10% of OHT recipients developed de novo DSAs or experienced an increase in pre-existing DSAs after COVID-19, with the majority occurring in unvaccinated patients (15% vs 2%). Further studies are necessary to substantiate our findings in an external cohort.

KW - COVID-19

KW - Donor specific antibody

KW - Heart transplant

UR - http://www.scopus.com/inward/record.url?scp=85138153241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138153241&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2022.101712

DO - 10.1016/j.trim.2022.101712

M3 - Article

C2 - 36100195

AN - SCOPUS:85138153241

SN - 0966-3274

VL - 75

JO - Transplant Immunology

JF - Transplant Immunology

M1 - 101712

ER -

COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this